According to IFC website, the United Laboratories International Holdings Limited is a leading generic pharmaceutical producer in China. TUL manufactures antibiotics finished products, insulin products, and active pharmaceutical ingredients and it is one of the largest penicillin-based antibiotics producers in China. The Company plans to upgrade and expand its manufacturing facilities in China, invest in the marketing of insulin products and spend on long-term research and development.
The United Laboratories International Holdings Limited manufactures insulin products, antibiotics, pharmaceutical intermediary products, and bulk medicine for domestic consumptions in China and for exports to overseas markets.
|Private Actor 1||Private Actor 1 Role||Private Actor 1 Sector||Relation||Private Actor 2||Private Actor 2 Role||Private Actor 2 Sector|
|-||-||-||-||The United Laboratories International Holdings Limited||Client||-|
The United Laboratories International Holdings Limited
No contact information provided at the time of disclosure.
ACCOUNTABILITY MECHANISM OF IFC
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/